Back to Search

A Phase Ib, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-Mutant Advanced Melanoma Who Have Received Anti-PD-1/PD-L1 Therapy

  • Protocol Number: 202011137
  • Principal Investigator: Ansstas, George
  • Cancer Types: Melanoma & Skin

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions